HC Wainwright Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $72.00

Halozyme Therapeutics (NASDAQ:HALO) had its price target upped by HC Wainwright from $70.00 to $72.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 24.35% from the stock’s previous close.

Other research analysts have also issued reports about the stock. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Down 0.7 %

HALO stock opened at $57.90 on Wednesday. Halozyme Therapeutics has a fifty-two week low of $35.50 and a fifty-two week high of $65.53. The company has a market capitalization of $7.37 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The business’s 50 day moving average price is $52.69 and its two-hundred day moving average price is $54.51. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%. As a group, analysts forecast that Halozyme Therapeutics will post 3.87 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $128,000. Novem Group bought a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $841,000. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $876,000. Two Sigma Advisers LP bought a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $282,000. Finally, Two Sigma Investments LP grew its position in Halozyme Therapeutics by 403.0% in the 4th quarter. Two Sigma Investments LP now owns 247,030 shares of the biopharmaceutical company’s stock worth $11,811,000 after purchasing an additional 197,918 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.